La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

AFT Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 6/6

AFT Pharmaceuticals ha un patrimonio netto totale di NZ$87.8M e un debito totale di NZ$28.2M, che porta il suo rapporto debito/patrimonio netto a 32.1%. Le sue attività totali e le sue passività totali sono rispettivamente NZ$165.3M e NZ$77.5M. L'EBIT di AFT Pharmaceuticals è NZ$24.2M rendendo il suo rapporto di copertura degli interessi 6.7. Ha liquidità e investimenti a breve termine pari a NZ$12.0M.

Informazioni chiave

32.1%

Rapporto debito/patrimonio netto

NZ$28.20m

Debito

Indice di copertura degli interessi	6.7x
Contanti	NZ$12.04m
Patrimonio netto	NZ$87.80m
Totale passività	NZ$77.46m
Totale attività	NZ$165.26m

Aggiornamenti recenti sulla salute finanziaria

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Recent updates

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Jul 26

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( NZ$105.7M ) di AFT superano le sue passività a breve termine ( NZ$46.1M ).

Passività a lungo termine: Le attività a breve termine di AFT ( NZ$105.7M ) superano le sue passività a lungo termine ( NZ$31.4M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 18.4% ) di AFT è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di AFT si è ridotto da 820.1% a 32.1% negli ultimi 5 anni.

Copertura del debito: Il debito di AFT è ben coperto dal flusso di cassa operativo ( 102.3% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di AFT sono ben coperti dall'EBIT ( 6.7 x copertura).

AFT Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Recent updates

Price target increased by 24% to NZ$4.60

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Upcoming dividend of NZ$0.016 per share

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 02, 2024

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Dividend of NZ$0.016 announced

Full year 2024 earnings released: EPS: NZ$0.15 (vs NZ$0.10 in FY 2023)

AFT Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 23, 2024

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Announces Board Changes

Independent Non-Executive Director recently sold NZ$109k worth of stock

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Consensus EPS estimates fall by 17%

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

Price target decreased to NZ$4.22

Consensus forecasts updated

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Price target decreased to NZ$5.51

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

AFT Pharmaceuticals Limited Update on Maxigesic IV Us Registration Filing

AFT Pharmaceuticals Limited Completes Pascomer Clinical Study

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

US FDA Seeks More Information on AFT Pharmaceuticals Limited's Maxigesic IV Application

Price target decreased to NZ$4.40

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Investor sentiment improved over the past week

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year to 31 March 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

Price target increased to NZ$5.88

AFT Pharmaceuticals Announces US Food and Drug Administration Approve Topical Treatment Indicated for Facial Angiofibroma

Independent Director recently bought NZ$66k worth of stock

Independent Director recently bought NZ$171k worth of stock

AFT Pharmaceuticals Limited Welcomes Australian Federal Court Appeal Success

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

First half 2022 earnings released: EPS NZ$0.04 (vs NZ$0.01 in 1H 2021)

Price target increased to NZ$5.88

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

AFT Pharmaceuticals Got First Regulatory Approval of Maxigesic Oral Liquid in Europe

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Full year 2021 earnings released

AFT Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year 2022

CFO & Company Secretary exercised options to buy NZ$205k worth of stock.

Consensus EPS estimates fall to NZ$0.092

Price target decreased to NZ$4.95

AFT Pharmaceuticals Revises Earnings Guidance for the Year to 31 March 2021

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

AFT Pharmaceuticals Signs an Exclusive Maxigesic IV Licensing Agreement for Eight New European Markets

New 90-day low: NZ$4.21

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

New 90-day high: NZ$5.51

AFT Pharmaceuticals Limited Appoints Anita Baldauf as Non-Executive Director

New 90-day low: NZ$4.55

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Analysts lower EPS estimates to NZ$0.11

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Revenue and earnings miss expectations

AFT Pharmaceuticals Limited Appoints Eddie Townslie as the Local Director of AFT Pharmaceuticals Europe

New 90-day high: NZ$5.46

AFT Pharmaceuticals Receives a US Food and Drug Administration Complete Response Letter Covering Its Application for the Approval of A Tablet Version of Its Maxigesic® Pain Relief Medication

AFT Pharmaceuticals Limited and Setek Sign Supply Agreement